Abstract |
The use of afala in complex treatment of patients with chronic prostatitis improves the efficiency of therapy and prolongs its positive results. The preparation is well tolerated, has no contraindication, and can be combined with other drugs. Afala is indicated for patients with stages II and IIIa chronic prostatitis from the first day of therapy.
|
Authors | E V Kul'chavenya |
Journal | Bulletin of experimental biology and medicine
(Bull Exp Biol Med)
Vol. 148
Issue 2
Pg. 315-7
(Aug 2009)
ISSN: 1573-8221 [Electronic] United States |
PMID | 20027357
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies
- Immunologic Factors
- afala
|
Topics |
- Adult
- Antibodies
(therapeutic use)
- Chronic Disease
- Humans
- Immunologic Factors
(therapeutic use)
- Male
- Middle Aged
- Pain
(drug therapy, pathology)
- Prostatitis
(drug therapy, metabolism, pathology)
- Treatment Outcome
|